CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Conivaptan Hydrochloride Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2022-03-14. Latest FDA row update: 2026-09-16.
FDA lists 1 package records, with companies: Cumberland Pharmaceuticals Inc.. Package NDCs: 66220-160-10.
FDA shortage reason: Delay in shipping of the drug
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc. | 66220-160-10 | Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10) | Unavailable | 2026-09-16 |
Source facts
Grouped generic ingredient: Conivaptan Hydrochloride Injection · 1 package records
Therapeutic categories: Cardiovascular
Dosage forms: Injection
Routes: Not stated
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.